These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 32144161)

  • 1. Fumarate Upregulates Surface Expression of ULBP2/ULBP5 by Scavenging Glutathione Antioxidant Capacity.
    Høgh RI; Droujinine A; Møller SH; Jepsen SD; Mellergaard M; Andresen L; Skov S
    J Immunol; 2020 Apr; 204(7):1746-1759. PubMed ID: 32144161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Natural Killer cell expression of ULBP2 is associated with a mature functional phenotype.
    Brennan K; McSharry BP; Keating S; Petrasca A; O'Reilly VP; Keane J; Doherty DG; Gardiner CM
    Hum Immunol; 2016 Oct; 77(10):876-885. PubMed ID: 27349945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A conserved WW domain-like motif regulates invariant chain-dependent cell-surface transport of the NKG2D ligand ULBP2.
    Uhlenbrock F; van Andel E; Andresen L; Skov S
    Mol Immunol; 2015 Aug; 66(2):418-27. PubMed ID: 25983110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling.
    Sullivan LB; Martinez-Garcia E; Nguyen H; Mullen AR; Dufour E; Sudarshan S; Licht JD; Deberardinis RJ; Chandel NS
    Mol Cell; 2013 Jul; 51(2):236-48. PubMed ID: 23747014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D.
    Heinemann A; Zhao F; Pechlivanis S; Eberle J; Steinle A; Diederichs S; Schadendorf D; Paschen A
    Cancer Res; 2012 Jan; 72(2):460-71. PubMed ID: 22102694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.
    Textor S; Fiegler N; Arnold A; Porgador A; Hofmann TG; Cerwenka A
    Cancer Res; 2011 Sep; 71(18):5998-6009. PubMed ID: 21764762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro.
    Brennan MS; Matos MF; Li B; Hronowski X; Gao B; Juhasz P; Rhodes KJ; Scannevin RH
    PLoS One; 2015; 10(3):e0120254. PubMed ID: 25793262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the alpha2 domain.
    Wittenbrink M; Spreu J; Steinle A
    Eur J Immunol; 2009 Jun; 39(6):1642-51. PubMed ID: 19424970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway.
    Xie X; Zhao Y; Ma CY; Xu XM; Zhang YQ; Wang CG; Jin J; Shen X; Gao JL; Li N; Sun ZJ; Dong DL
    Br J Pharmacol; 2015 Aug; 172(15):3929-43. PubMed ID: 25953698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dimethyl Fumarate Controls the NRF2/DJ-1 Axis in Cancer Cells: Therapeutic Applications.
    Saidu NE; Noé G; Cerles O; Cabel L; Kavian-Tessler N; Chouzenoux S; Bahuaud M; Chéreau C; Nicco C; Leroy K; Borghese B; Goldwasser F; Batteux F; Alexandre J
    Mol Cancer Ther; 2017 Mar; 16(3):529-539. PubMed ID: 28069874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells.
    Molfetta R; Quatrini L; Capuano C; Gasparrini F; Zitti B; Zingoni A; Galandrini R; Santoni A; Paolini R
    Eur J Immunol; 2014 Sep; 44(9):2761-70. PubMed ID: 24846123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of NKG2D-ligand cell surface expression by intracellular calcium after HDAC-inhibitor treatment.
    Jensen H; Hagemann-Jensen M; Lauridsen F; Skov S
    Mol Immunol; 2013 Mar; 53(3):255-64. PubMed ID: 22964480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
    Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
    FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2.
    Li H; Lakshmikanth T; Garofalo C; Enge M; Spinnler C; Anichini A; Szekely L; Kärre K; Carbone E; Selivanova G
    Cell Cycle; 2011 Oct; 10(19):3346-58. PubMed ID: 21941086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
    Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
    Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
    Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
    Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical validation and expression profiling of NKG2D ligands in a wide spectrum of human epithelial neoplasms.
    Fujita H; Hatanaka Y; Sutoh Y; Suzuki Y; Oba K; Hatanaka KC; Mitsuhashi T; Otsuka N; Fugo K; Kasahara M; Matsuno Y
    J Histochem Cytochem; 2015 Mar; 63(3):217-27. PubMed ID: 25473094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.
    Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C
    J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
    Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
    Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The RNA binding protein IMP3 facilitates tumor immune escape by downregulating the stress-induced ligands ULPB2 and MICB.
    Schmiedel D; Tai J; Yamin R; Berhani O; Bauman Y; Mandelboim O
    Elife; 2016 Mar; 5():. PubMed ID: 26982091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.